What is it about?
For the first time, we present selective progesterone receptor modulator as a potential treatment for Premenstrual Dysphoric Disorder (PMDD), a common mood disorder affecting women in the late luteal phase of the menstrual cycle during their reproductive age.
Featured Image
Photo by Ashton Bingham on Unsplash
Why is it important?
The research results will be an important piece of the puzzle of improving our understanding of the mechanisms behind PMDD, the researchers say. Today, the first-line treatment for PMDD is serotonin reuptake inhibitors. Although these drugs are very effective, they are not suitable for all women and additional treatment options are of value. In addition, it would be desirable to have a treatment that more specifically addresses the mechanisms underlying this psychiatric disorder.
Perspectives
Looking ahead, the researchers are currently investigating how progesterone receptor modulator affects the brain in women with PMDD. By neuroimaging the brain of these patients before and during treatment, using magnetic resonance imaging, the researchers aim to define structural and functional brain signatures that can explain the relief of PMDD symptoms.
Erika Comasco
Uppsala Universitet
Read the Original
This page is a summary of: Ulipristal Acetate for Treatment of Premenstrual Dysphoric Disorder: A Proof-of-Concept Randomized Controlled Trial, American Journal of Psychiatry, December 2020, American Psychiatric Association,
DOI: 10.1176/appi.ajp.2020.20030286.
You can read the full text:
Contributors
The following have contributed to this page
